289 related articles for article (PubMed ID: 8489326)
1. Efficacy of phenelzine and haloperidol in borderline personality disorder.
Soloff PH; Cornelius J; George A; Nathan S; Perel JM; Ulrich RF
Arch Gen Psychiatry; 1993 May; 50(5):377-85. PubMed ID: 8489326
[TBL] [Abstract][Full Text] [Related]
2. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.
Cornelius JR; Soloff PH; Perel JM; Ulrich RF
Am J Psychiatry; 1993 Dec; 150(12):1843-8. PubMed ID: 8238640
[TBL] [Abstract][Full Text] [Related]
3. Haloperidol vs. phenelzine in continuation therapy of borderline disorder.
Cornelius JR; Soloff PH; George A; Ulrich RF; Perel JM
Psychopharmacol Bull; 1993; 29(2):333-7. PubMed ID: 8290683
[TBL] [Abstract][Full Text] [Related]
4. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study.
Frankenburg FR; Zanarini MC
J Clin Psychiatry; 2002 May; 63(5):442-6. PubMed ID: 12019669
[TBL] [Abstract][Full Text] [Related]
5. Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo.
Soloff PH; George A; Nathan RS; Schulz PM; Ulrich RF; Perel JM
Arch Gen Psychiatry; 1986 Jul; 43(7):691-7. PubMed ID: 3521532
[TBL] [Abstract][Full Text] [Related]
6. Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response.
Soloff PH; George A; Nathan S; Schulz PM; Cornelius JR; Herring J; Perel JM
J Clin Psychopharmacol; 1989 Aug; 9(4):238-46. PubMed ID: 2768542
[TBL] [Abstract][Full Text] [Related]
7. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.
Jarrett RB; Schaffer M; McIntire D; Witt-Browder A; Kraft D; Risser RC
Arch Gen Psychiatry; 1999 May; 56(5):431-7. PubMed ID: 10232298
[TBL] [Abstract][Full Text] [Related]
8. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.
Nickel MK; Muehlbacher M; Nickel C; Kettler C; Pedrosa Gil F; Bachler E; Buschmann W; Rother N; Fartacek R; Egger C; Anvar J; Rother WK; Loew TH; Kaplan P
Am J Psychiatry; 2006 May; 163(5):833-8. PubMed ID: 16648324
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial.
Shafti SS; Shahveisi B
J Clin Psychopharmacol; 2010 Feb; 30(1):44-7. PubMed ID: 20075647
[TBL] [Abstract][Full Text] [Related]
10. Phenelzine v imipramine in atypical depression. A preliminary report.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison W; Rabkin J; Tricamo E; Markowitz JS; Klein DF
Arch Gen Psychiatry; 1984 Jul; 41(7):669-77. PubMed ID: 6375621
[TBL] [Abstract][Full Text] [Related]
11. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target.
Villeneuve E; Lemelin S
J Clin Psychiatry; 2005 Oct; 66(10):1298-303. PubMed ID: 16259544
[TBL] [Abstract][Full Text] [Related]
12. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder.
Hollander E; Allen A; Lopez RP; Bienstock CA; Grossman R; Siever LJ; Merkatz L; Stein DJ
J Clin Psychiatry; 2001 Mar; 62(3):199-203. PubMed ID: 11305707
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder.
Van den Eynde F; Senturk V; Naudts K; Vogels C; Bernagie K; Thas O; van Heeringen C; Audenaert K
J Clin Psychopharmacol; 2008 Apr; 28(2):147-55. PubMed ID: 18344724
[TBL] [Abstract][Full Text] [Related]
14. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression.
Parsons B; Quitkin FM; McGrath PJ; Stewart JW; Tricamo E; Ocepek-Welikson K; Harrison W; Rabkin JG; Wager SG; Nunes E
Psychopharmacol Bull; 1989; 25(4):524-34. PubMed ID: 2698483
[TBL] [Abstract][Full Text] [Related]
15. Phenelzine for chronic depression: a study of continuation treatment.
Harrison W; Rabkin J; Stewart JW; McGrath PJ; Tricamo E; Quitkin F
J Clin Psychiatry; 1986 Jul; 47(7):346-9. PubMed ID: 3522558
[TBL] [Abstract][Full Text] [Related]
16. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder.
Hollander E; Swann AC; Coccaro EF; Jiang P; Smith TB
Am J Psychiatry; 2005 Mar; 162(3):621-4. PubMed ID: 15741486
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant specificity in atypical depression.
Liebowitz MR; Quitkin FM; Stewart JW; McGrath PJ; Harrison WM; Markowitz JS; Rabkin JG; Tricamo E; Goetz DM; Klein DF
Arch Gen Psychiatry; 1988 Feb; 45(2):129-37. PubMed ID: 3276282
[TBL] [Abstract][Full Text] [Related]
18. Affective instability and impulsivity in borderline personality and bipolar II disorders: similarities and differences.
Henry C; Mitropoulou V; New AS; Koenigsberg HW; Silverman J; Siever LJ
J Psychiatr Res; 2001; 35(6):307-12. PubMed ID: 11684137
[TBL] [Abstract][Full Text] [Related]
19. Risk factors for suicidal behavior in borderline personality disorder.
Soloff PH; Lis JA; Kelly T; Cornelius J; Ulrich R
Am J Psychiatry; 1994 Sep; 151(9):1316-23. PubMed ID: 8067487
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.
Bellino S; Paradiso E; Bogetto F
J Clin Psychiatry; 2006 Jul; 67(7):1042-6. PubMed ID: 16889446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
